Cerus Current Ratio 2012-2025 | CERS
Cerus current ratio from 2012 to 2025. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Cerus Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2025-09-30 | $0.17B | $0.09B | 1.89 |
| 2025-06-30 | $0.17B | $0.08B | 2.00 |
| 2025-03-31 | $0.16B | $0.07B | 2.32 |
| 2024-12-31 | $0.15B | $0.06B | 2.39 |
| 2024-09-30 | $0.14B | $0.05B | 2.59 |
| 2024-06-30 | $0.14B | $0.05B | 2.51 |
| 2024-03-31 | $0.14B | $0.06B | 2.41 |
| 2023-12-31 | $0.14B | $0.07B | 2.14 |
| 2023-09-30 | $0.15B | $0.08B | 1.88 |
| 2023-06-30 | $0.15B | $0.08B | 2.01 |
| 2023-03-31 | $0.16B | $0.08B | 2.09 |
| 2022-12-31 | $0.17B | $0.12B | 1.45 |
| 2022-09-30 | $0.17B | $0.10B | 1.73 |
| 2022-06-30 | $0.17B | $0.08B | 2.08 |
| 2022-03-31 | $0.17B | $0.07B | 2.59 |
| 2021-12-31 | $0.19B | $0.08B | 2.38 |
| 2021-09-30 | $0.18B | $0.07B | 2.75 |
| 2021-06-30 | $0.19B | $0.07B | 2.82 |
| 2021-03-31 | $0.18B | $0.06B | 3.31 |
| 2020-12-31 | $0.18B | $0.06B | 3.06 |
| 2020-09-30 | $0.18B | $0.05B | 3.84 |
| 2020-06-30 | $0.18B | $0.04B | 4.15 |
| 2020-03-31 | $0.18B | $0.05B | 3.96 |
| 2019-12-31 | $0.13B | $0.05B | 2.55 |
| 2019-09-30 | $0.13B | $0.05B | 2.77 |
| 2019-06-30 | $0.14B | $0.05B | 2.68 |
| 2019-03-31 | $0.14B | $0.05B | 2.84 |
| 2018-12-31 | $0.15B | $0.05B | 2.79 |
| 2018-09-30 | $0.15B | $0.04B | 3.48 |
| 2018-06-30 | $0.14B | $0.03B | 5.03 |
| 2018-03-31 | $0.13B | $0.02B | 5.66 |
| 2017-12-31 | $0.09B | $0.02B | 3.89 |
| 2017-09-30 | $0.09B | $0.02B | 3.71 |
| 2017-06-30 | $0.07B | $0.03B | 2.94 |
| 2017-03-31 | $0.08B | $0.03B | 2.86 |
| 2016-12-31 | $0.09B | $0.03B | 3.50 |
| 2016-09-30 | $0.11B | $0.02B | 4.72 |
| 2016-06-30 | $0.11B | $0.03B | 4.36 |
| 2016-03-31 | $0.12B | $0.02B | 5.23 |
| 2015-12-31 | $0.13B | $0.02B | 5.97 |
| 2015-09-30 | $0.13B | $0.02B | 6.45 |
| 2015-06-30 | $0.14B | $0.02B | 6.50 |
| 2015-03-31 | $0.14B | $0.02B | 5.99 |
| 2014-12-31 | $0.08B | $0.03B | 2.57 |
| 2014-09-30 | $0.07B | $0.02B | 3.44 |
| 2014-06-30 | $0.07B | $0.02B | 3.24 |
| 2014-03-31 | $0.07B | $0.03B | 2.46 |
| 2013-12-31 | $0.08B | $0.04B | 1.98 |
| 2013-09-30 | $0.08B | $0.04B | 1.75 |
| 2013-06-30 | $0.08B | $0.03B | 2.95 |
| 2013-03-31 | $0.09B | $0.03B | 3.16 |
| 2012-12-31 | $0.04B | $0.03B | 1.72 |
| 2012-09-30 | $0.04B | $0.03B | 1.60 |
| 2012-06-30 | $0.04B | $0.02B | 1.80 |
| 2012-03-31 | $0.05B | $0.03B | 1.70 |
| 2011-12-31 | $0.04B | $0.02B | 1.88 |
| 2011-09-30 | $0.03B | $0.01B | 2.16 |
| 2011-06-30 | $0.03B | $0.02B | 1.49 |
| 2011-03-31 | $0.04B | $0.02B | 1.77 |
| 2010-12-31 | $0.04B | $0.02B | 2.12 |
| 2010-09-30 | $0.03B | $0.02B | 1.72 |
| 2010-06-30 | $0.03B | $0.01B | 2.07 |
| 2010-03-31 | $0.03B | $0.01B | 2.79 |
| 2009-12-31 | $0.03B | $0.01B | 2.51 |
| 2009-09-30 | $0.04B | $0.02B | 2.25 |
| 2009-06-30 | $0.03B | $0.01B | 2.33 |
| 2009-03-31 | $0.03B | $0.01B | 2.94 |
| 2008-12-31 | $0.04B | $0.01B | 3.26 |
| 2008-09-30 | $0.05B | $0.01B | 3.82 |
| 2008-06-30 | $0.06B | $0.02B | 3.69 |
| 2008-03-31 | $0.07B | $0.01B | 4.74 |
| 2007-12-31 | $0.07B | $0.02B | 4.03 |
| 2007-09-30 | $0.08B | $0.02B | 5.13 |
| 2007-06-30 | $0.09B | $0.01B | 6.22 |
| 2007-03-31 | $0.09B | $0.01B | 8.36 |
| 2006-12-31 | $0.10B | $0.02B | 6.94 |
| 2006-09-30 | $0.08B | $0.02B | 5.13 |
| 2006-06-30 | $0.08B | $0.02B | 4.85 |
| 2006-03-31 | $0.09B | $0.02B | 4.26 |
| 2005-12-31 | $0.05B | $0.02B | 2.19 |
| 2005-09-30 | $0.05B | $0.01B | 4.10 |
| 2005-06-30 | $0.06B | $0.01B | 4.10 |
| 2005-03-31 | $0.06B | $0.02B | 3.98 |
| 2004-12-31 | $0.10B | $0.08B | 1.31 |
| 2004-09-30 | $0.09B | $0.07B | 1.36 |
| 2004-06-30 | $0.10B | $0.07B | 1.44 |
| 2004-03-31 | $0.11B | $0.07B | 1.64 |
| 2003-12-31 | $0.12B | $0.07B | 1.76 |
| 2003-09-30 | $0.13B | $0.07B | 1.86 |
| 2003-06-30 | $0.14B | $0.02B | 9.44 |
| 2003-03-31 | $0.10B | $0.02B | 6.87 |
| 2002-12-31 | $0.07B | $0.02B | 4.01 |
| 2002-09-30 | $0.08B | $0.02B | 4.58 |
| 2002-06-30 | $0.10B | $0.02B | 5.22 |
| 2002-03-31 | $0.11B | $0.02B | 6.55 |
| 2001-12-31 | $0.13B | $0.02B | 7.60 |
| 2001-09-30 | $0.14B | $0.02B | 8.11 |
| 2001-06-30 | $0.15B | $0.02B | 9.96 |
| 2001-03-31 | $0.08B | $0.01B | 6.40 |
| 2000-12-31 | $0.09B | $0.01B | 7.49 |
| 2000-09-30 | $0.10B | $0.01B | 8.50 |
| 2000-06-30 | $0.05B | $0.01B | 4.86 |
| 2000-03-31 | $0.06B | $0.01B | 6.41 |
| 1999-12-31 | $0.04B | $0.01B | 4.67 |
| 1999-09-30 | $0.05B | $0.01B | 5.24 |
| 1999-06-30 | $0.06B | $0.01B | 4.27 |
| 1999-03-31 | $0.03B | $0.02B | 1.29 |
| 1998-12-31 | $0.02B | $0.02B | 1.03 |
| 1998-09-30 | $0.02B | $0.02B | 1.41 |
| 1998-06-30 | $0.02B | $0.01B | 3.33 |
| 1998-03-31 | $0.02B | $0.01B | 4.50 |
| 1997-12-31 | $0.03B | $0.01B | 5.46 |
| 1997-09-30 | $0.02B | $0.00B | 6.71 |
| 1997-06-30 | $0.03B | $0.00B | 6.11 |
| 1997-03-31 | $0.03B | $0.00B | 7.33 |
| 1996-12-31 | $0.01B | $0.00B | 1.68 |
| 1996-09-30 | $0.00B | 0.00 | |
| 1996-06-30 | $0.00B | 0.00 | |
| 1996-03-31 | $0.00B | 0.00 | |
| 1995-12-31 | $0.01B | $0.00B | 3.74 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.430B | $0.180B |
| Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $195.936B | 21.88 |
| EssilorLuxottica (ESLOY) | France | $142.091B | 0.00 |
| Stryker (SYK) | United States | $140.083B | 26.86 |
| Medtronic (MDT) | Ireland | $127.548B | 17.67 |
| Boston Scientific (BSX) | United States | $110.783B | 24.50 |
| Medline (MDLN) | United States | $58.526B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $48.093B | 0.00 |
| ResMed (RMD) | United States | $36.791B | 24.57 |
| GE HealthCare Technologies (GEHC) | United States | $36.615B | 17.54 |
| Agilent Technologies (A) | United States | $35.584B | 22.55 |
| Koninklijke Philips (PHG) | Netherlands | $30.091B | 17.86 |
| Terumo (TRUMY) | Japan | $21.610B | 25.26 |
| Zimmer Biomet Holdings (ZBH) | United States | $19.115B | 11.76 |
| Insulet (PODD) | United States | $17.076B | 53.00 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $15.372B | 0.00 |
| Baxter (BAX) | United States | $10.182B | 8.72 |
| Sunny Optical Technology (SNPTF) | China | $8.485B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.921B | 25.86 |
| Demant (WILYY) | Denmark | $6.042B | 0.00 |
| Envista Holdings (NVST) | United States | $4.747B | 24.14 |
| Lantheus Holdings (LNTH) | United States | $4.601B | 14.02 |
| BillionToOne (BLLN) | United States | $4.056B | 0.00 |
| ICU Medical (ICUI) | United States | $3.577B | 22.71 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.263B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.160B | 14.91 |
| Haemonetics (HAE) | United States | $2.684B | 11.74 |
| Neogen (NEOG) | United States | $2.380B | 52.10 |
| Phibro Animal Health (PAHC) | United States | $2.118B | 18.66 |
| Perrigo (PRGO) | Ireland | $2.001B | 5.01 |
| LeMaitre Vascular (LMAT) | United States | $1.989B | 40.03 |
| Curaleaf Holdings (CURLF) | Canada | $1.642B | 0.00 |
| AtriCure (ATRC) | United States | $1.623B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.602B | 11.12 |
| Kestra Medical Technologies (KMTS) | United States | $1.571B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.446B | 63.36 |
| AdaptHealth (AHCO) | United States | $1.381B | 20.00 |
| Lumexa Imaging Holdings (LMRI) | United States | $1.358B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.070B | 317.57 |
| Capricor Therapeutics (CAPR) | United States | $1.026B | 0.00 |
| InMode (INMD) | Israel | $0.906B | 9.93 |
| Tilray Brands (TLRY) | Canada | $0.875B | 0.00 |
| Valneva SE (VALN) | France | $0.868B | 0.00 |
| Omeros (OMER) | United States | $0.829B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.757B | 0.00 |
| CeriBell (CBLL) | United States | $0.733B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.566B | 13.52 |
| Brainsway (BWAY) | Israel | $0.451B | 76.63 |
| Canopy Growth (CGC) | Canada | $0.436B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.396B | 0.00 |
| SNDL (SNDL) | Canada | $0.386B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.361B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.328B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.315B | 25.09 |
| Evolus (EOLS) | United States | $0.279B | 0.00 |
| Quanterix (QTRX) | United States | $0.268B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.243B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Sanuwave Health (SNWV) | United States | $0.213B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.205B | 18.42 |
| High Tide (HITI) | Canada | $0.203B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.201B | 59.17 |
| OraSure Technologies (OSUR) | United States | $0.197B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.182B | 0.00 |
| Organigram Global (OGI) | Canada | $0.174B | 0.00 |
| Accendra Health (ACH) | United States | $0.173B | 1.74 |
| Vireo Growth (VREOF) | United States | $0.170B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.168B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.157B | 0.00 |
| Apyx Medical (APYX) | United States | $0.142B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.134B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.129B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.42 |
| MacroGenics (MGNX) | United States | $0.108B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.100B | 0.00 |
| Biote (BTMD) | United States | $0.097B | 4.26 |
| Exagen (XGN) | United States | $0.074B | 0.00 |
| ImmuCell (ICCC) | United States | $0.060B | 25.39 |
| Sharps Technology (STSS) | United States | $0.051B | 0.00 |
| Nephros (NEPH) | United States | $0.044B | 31.54 |
| Cytosorbents (CTSO) | United States | $0.040B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.040B | 0.00 |
| Veru (VERU) | United States | $0.037B | 0.00 |
| Modular Medical (MODD) | United States | $0.035B | 0.00 |
| United-Guardian (UG) | United States | $0.030B | 15.35 |
| Jin Medical (ZJYL) | China | $0.022B | 0.00 |
| Bonk (BNKK) | United States | $0.021B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.014B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.009B | 0.00 |
| INLIF (INLF) | China | $0.007B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| Agape ATP (ATPC) | $0.002B | 0.00 | |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |